Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete Pathologic response after Neoadjuvant chemotherapy

被引:82
作者
Goldstein, Neal S.
Decker, David
Severson, Dawn
Schell, Scoff
Vicini, Frank
Margolis, Jeffrey
Dekhne, Nayana S.
机构
[1] William Beaumont Hosp, Dept Anat Pathol, Royal Oak, MI 48073 USA
[2] William Beaumont Hosp, Dept Med Oncol, Royal Oak, MI 48072 USA
[3] William Beaumont Hosp, Dept Surg Oncol, Royal Oak, MI 48072 USA
[4] William Beaumont Hosp, Dept Radiat Oncol, Royal Oak, MI 48072 USA
关键词
molecular classification system; invasive breast cancer; complete pathologic response; neoadjuvant chemotherapy; receptor status;
D O I
10.1002/cncr.22981
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. The molecular classification system categorizes invasive breast carcinomas according to their key driving biomarkers. In the current study, the authors evaluated whether response to neoadjuvant chemotherapy was correlated with the molecular classification groups. METHODS. Using immunohistochemistry, the molecular classification group (luminal-A, luminal-B, HER-2-variant, HER-2-classic, and basal phenotype) was retrospectively determined in 68 breast cancer patients who received neoadjuvant treatment. RESULTS. A total of 28 carcinoma patients (41.2%) achieved a compete pathologic response (CPR), including 2 of 15 patients classified as having luminal-A (13.3%), 4 of 16 patients classified as having luminal-B (25.0%), 10 of 12 patients classified as having HER-2-classic (83.3%), none of the 4 patients classified as having HER-2-variant, and 12 of 21 patients classified as having basal phenotype (57.1%) neoplasms. The CPR rate among patients with the HER-2-classic and basal neoplasms was 67% (22 of 33 neoplasms), compared with 17.1% (6 of 35 neoplasms) in the non-HER-2-classic/basal combined group (P < .001). Eleven carcinomas were initially diagnosed as invasive lobular carcinomas (pleomorphic and classic), 4 of which were luminal-A, 4 of which were luminal-B, 2 of which were HER-2-classic, and 1 of which was basal. On review, only 3 of these 11 cases remained classified as classic lobular carcinoma,;01 of which were classified as luminal-A, and none of these patients achieved a CPR. Four of the other 8 patients achieved a CPR. CONCLUSIONS. The molecular classification system is useful for identifying carcinoma patients who are most likely and those who are least likely to achieve a CPR. In the current study, all the morphologically classic lobular carcinomas were classified as luminal-A neoplasms, which may explain the low rate of CPR reported.
引用
收藏
页码:1687 / 1696
页数:10
相关论文
共 62 条
  • [51] Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with Neoadjuvant chemotherapy for breast cancer
    Rouzier, Roman
    Pusztai, Lajos
    Garbay, Jean-Remi
    Delaloge, Suzette
    Hunt, Kelly K.
    Hortobagyi, Gabriel N.
    Berry, Donald
    Kuerer, Henry M.
    [J]. CANCER, 2006, 107 (07) : 1459 - 1466
  • [52] Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel
    Smith, IC
    Heys, SD
    Hutckeon, AW
    Miller, ID
    Payne, S
    Gilbert, FJ
    Ah-See, AK
    Eremin, O
    Walker, LG
    Sarkar, TK
    Eggleton, SP
    Ogston, KN
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (06) : 1456 - 1466
  • [53] Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial
    Smith, IE
    Dowsett, M
    Ebbs, SR
    Dixon, JM
    Skene, A
    Blohmer, JU
    Ashley, SE
    Francis, S
    Boeddinghaus, I
    Walsh, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) : 5108 - 5116
  • [54] Molecular portraits of breast cancer: tumour subtypes as distinct disease entities
    Sorlie, T
    [J]. EUROPEAN JOURNAL OF CANCER, 2004, 40 (18) : 2667 - 2675
  • [55] Repeated observation of breast tumor subtypes in independent gene expression data sets
    Sorlie, T
    Tibshirani, R
    Parker, J
    Hastie, T
    Marron, JS
    Nobel, A
    Deng, S
    Johnsen, H
    Pesich, R
    Geisler, S
    Demeter, J
    Perou, CM
    Lonning, PE
    Brown, PO
    Borresen-Dale, AL
    Botstein, D
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (14) : 8418 - 8423
  • [56] Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
    Sorlie, T
    Perou, CM
    Tibshirani, R
    Aas, T
    Geisler, S
    Johnsen, H
    Hastie, T
    Eisen, MB
    van de Rijn, M
    Jeffrey, SS
    Thorsen, T
    Quist, H
    Matese, JC
    Brown, PO
    Botstein, D
    Lonning, PE
    Borresen-Dale, AL
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (19) : 10869 - 10874
  • [57] Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms
    Sorlie, Therese
    Wang, Yulei
    Xiao, Chunlin
    Johnsen, Hilde
    Naume, Bjorn
    Samaha, Raymond R.
    Borresen-Dale, Anne-Lise
    [J]. BMC GENOMICS, 2006, 7 (1)
  • [58] Stearns V, 2003, CLIN CANCER RES, V9, P124
  • [59] Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas:: a retrospective study on 860 patients from one institution
    Tubiana-Hulin, M.
    Stevens, D.
    Lasry, S.
    Guinebretiere, J. M.
    Bouita, L.
    Cohen-Solal, C.
    Cherel, P.
    Rouesse, J.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 (08) : 1228 - 1233
  • [60] *WHO, 2003, CLASS TUM PATH GEN T, P9